Co-Founder and Chief Executive Officer
Shawn focuses on biotechnology, specialty pharmaceuticals and new technologies in life sciences. Previously, he served as Head of Investment and Merchant Banking at Noble Life Science Partners, a division of Noble Capital Markets. Prior to Noble, he was a Founding Partner at Variant Research Corporation and Senior Vice President of Avalon Research Group, both of which focused on long and short life sciences equity research.
Shawn is highly proficient in scientific and corporate due diligence and leverages proprietary relationships with scientific key opinion leaders and life science executives. For more than 20 years, he has demonstrated an ability to create and identify emerging life sciences companies with successful management teams, milestone outcomes and investment returns. Shawn has invested and raised capital for life sciences companies that has resulted in significant shareholder equity and valuations of over $1 billion.
Shawn earned his degree in Business Administration from the University of Denver. Shawn also serves as a Managing Director on Wilmington Capital Securities’ Life Sciences Investment Banking Division and holds FINRA series 7, 63 and 79 licenses.
Co-Founder and Partner
Menachem focuses on medical and healthcare technology. He has 20 years’ experience in the securities and finance industry, most recently as Founder and Portfolio Manager of Ahava Investment Partners where he meaningfully outperformed its benchmark index over a 5-year period. Prior to Ahava, Menachem was a Managing Partner of the merchant bank Littlebanc Advisors, and a VP of Investment Banking at Ladenburg Thalmann & Co., raising capital for emerging life sciences and technology companies.
Prior to joining Ladenburg, Menachem leveraged his extensive contacts and relationships with institutional investors in a variety of contexts, including as a hybrid trader with RBC Capital Markets and a Senior VP of institutional research sales at Avalon Research Group. There, he was instrumental in the rapid growth and development of the firm. He has built an extensive information network of contacts and relationships covering both public and private companies.
Menachem is a graduate of the Rabbinical College of America. He serves on Wilmington Capital Securities’ Equity Capital Life Sciences Division and holds FINRA series 7 and 63 licenses.
Matt joins Allele with 10 years of experience in the financial industry. Prior to Allele, Matt led initiatives at Noble Capital Markets focused on biotechnology and specialty pharmaceuticals equity research sales, where he honed his understanding of what drives the intersection of innovation and markets. Over the course of his career, Matt has developed a comprehensive network of executives, thoughts leaders, as well as institutional and accredited investors focused on life sciences. Matt began his career working at Ipac Financial Planning, a specialty wealth management firm in Hong Kong. Following Ipac, he worked for United Capital Financial Advisors, where he was responsible for both local and national growth initiatives.
Matt has received an M.S. in Biotechnology at Johns Hopkins University and also received a B.B.A in Entrepreneurship and a B.A in Mathematics from Florida Atlantic University, where his honors thesis consisted of original research in the area of Graph Theory. Matt serves on Wilmington Capital Securities’ Life Sciences Investment Banking Division. Matt is a Level II CAIA candidate and holds FINRA Series 7, 79, and 63 licenses.
Chief Operating Officer
Brian joined Allele Capital in 2020, focusing on developing and analyzing data driven themes in the life science industry. He also contributes to client deliverables and strategy, with a specialized focus on financial modeling and strategic market intelligence.
Brian graduated from Florida Atlantic University (FAU) with a BS in Finance and a BS in Economics, magna cum laude. He later earned a Master of Science in Finance degree at FAU, where he focused on factor modeling, derivative pricing, and valuation modeling. Brian also serves on Wilmington Capital Securities’ Life Sciences Division and holds FINRA Series 7 and 63 licenses.
Tom brings over 25 years of capital markets and investment banking expertise to Allele. Since 2012, he has focused on the life sciences sector and has specialized in raising equity and debt for public and private biopharma, specialty pharma, medtech, and medical device companies. Tom has extensive relationships with Family Offices, Private Equity, Venture Capital, Royalty, and Specialty Hedge Funds. Prior to that, Tom was focused on SPACs (Special Purpose Acquisition Companies) and specialized in the institutional placement of the IPOs and daily trading of SPACs. Tom advised management teams and transitioned institutional shareholder bases during the private to public company merger process. Prior to that, Tom was a financial advisor for independent and bulge bracket investment firms, including National Financial Partners, Raymond James, Lehman Brothers, and Paine Webber.
Tom is a graduate of the Isenberg School of Management at The University of Massachusetts, Amherst. Tom also serves on Wilmington Capital Securities’ Life Sciences Investment Banking Division and holds FINRA series 7, 79, and 63 licenses.
Ankit Bhargava, MD
Dr. Bhargava brings over 5 years of progressively senior positions in strategy, due diligence and advisory in the life sciences industry. Prior to joining Allele, he was a Manager at Pointe Advisory, where he focused extensively on clinical trials in oncology and rare disease. Prior to Pointe Advisory, he worked at Ana Health as Head of Business Development and Medical Director, and as a Founder and Managing Partner at BharCode, a proprietary healthcare application linking medical residents and physicians with home-bound patients.
Dr. Bhargava was a resident physician at Eastern Virginia Medical School and conducted his postdoctoral research at the University of Chicago related to oncological repercussions of inflammatory bowel disease treatment. He earned his Doctorate of Medicine at the University of Windsor School of Medicine, where he finished basic science coursework at top of his class, and earned US Medical Licensing Examination step 1 and 2 scores in the 99th percentile. He also holds a Bachelor of Science in Biology from Indiana University. He serves on Wilmington Capital Securities’ Equity Capital Life Sciences Division and holds FINRA Series 7 and 63 licenses.
Andrew joined Allele in 2023 as a Director and brings over 5 years of experience in progressively senior positions in market research, private equity, business development, capital markets strategy, and investor relations. Prior to Allele, Andrew was an Associate Director at LifeSci Advisors where he focused on advising both private and public companies in the life sciences sector with their investor relations and capital markets strategy. He worked with companies at all stages and therapeutic focuses, starting as early as private companies raising series A financings all the way to assisting public companies launch their commercial stage assets. Prior to LifeSci Advisors, Andrew was the Business Development Associate at AGC Partners, a global technology investment bank focused on M&A and private equity. In this role he worked to develop relationships with early-stage private companies needing to raise capital as well as engaged with institutional investors to assist in their portfolio strategy.
Andrew graduated from the University of New Hampshire with a B.S. in Business Administration and a dual concentration in Finance and Business Analytics where he also was selected by his peers to give the senior toast for the Peter T Paul School of Business and Economics. Andrew played lacrosse all 4 years at the University of New Hampshire as well as was a member of the UNH Sales Club.
Director of Business Development
Kumar joined Allele in 2020 focused on raising capital for promising life science companies through our executing broker-dealer. Kumar has developed extensive relationships with accredited and institutional investors who seek early access to innovative science that can translate into therapeutic solutions to treat disease. Previously, he served as a broker at Noble Capital Markets, where he raised money for emerging companies in their Life Science Division. Prior to Noble, he was an Investment Associate at Paulson Investment Company, where he raised capital for private and public companies in biotechnology, medical device and real estate. He has helped finance a dozen companies in therapeutic categories ranging from diabetes to oncology.
Kumar studied Business Administration at Northeastern University. He serves on Wilmington Capital Securities’ Equity Capital Life Sciences Division and holds FINRA series 7 and 63 licenses.
Daniel joined Allele Capital in 2023 as an Analyst, focused on analyzing various market trends in life science capital markets. Daniel graduated Magna Cum Laude from Nova Southeastern University with a B.S.B.A in Finance and a Minor in Economics, where he was a member of the Phi Beta Kappa and Beta Gamma Sigma Honor Societies, and member of NSU's Inaugural Student Managed Investment Fund.
Before his undergraduate studies, Daniel served 5 years in the United States Marine Corps as an Infantryman and member of 3rd Battalion, 4th Marines’ Scout Sniper Platoon. After the Marine Corps, Daniel contracted with the U.S. Department of State in Iraq and Afghanistan.